Clinical Trial Update: A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 trial of Mitapivat in participants with sickle cell disease and nephropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephropathy
• Sickle Cell Disease

Drugs mentioned

• Mitapivat (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Sickle Cell Disease, Nephropathy | Phase 2 | Status: WITHDRAWN